.@AmerGeriatrics commends the @US_FDA for authorizing 2 #COVID19 vaccines & expresses its support for the @CDCgov #ACIP's recommendations on groups that should be prioritized for #vaccination in the U.S. https://bit.ly/3h6CiiG
New York (Dec. 21, 2020) —The American Geriatrics Society today commends the U.S. Food and Drug Administration for its speedy, but thorough and transparent emergency use authorization of two COVID-19 vaccines and expresses its support for the CDC Advisory Committee on Immunization Practices’ (ACIP) recommendations on groups that should be prioritized for vaccination in the initial phases of the U.S. COVID-19 vaccination program.
“An independent expert advisory board, FDA officials, and members of the ACIP have now vetted the available data for both the Pfizer and Moderna vaccines, and the AGS trusts the science behind them. We are happy to note that adults ages 65 and older comprised at least 21 percent of participants in Phase 3 clinical trials, and both vaccines demonstrated at least 86.5 percent efficacy in that age group,” said AGS President Annette Medina-Walpole, MD, AGSF. “Based on these results, we encourage older adults to get vaccinated when the vaccine becomes available to them.”